Rafael Gegamovich Oganov

Rafael Gegamovich Oganov

Auto-generated profile, based on publicly available information

Rafael Gegamovich Oganov

National Research Centre for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2015 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
KKKornelia P. Kotseva
Kornelia P. Kotseva
DWDavid Wood
David Wood
DBDirk De Bacquer
Dirk De Bacquer
GBGuy De Backer
Guy De Backer
LRLars Rydén
Lars Rydén
OIon behalf of the EUROASPIRE Investigators
on behalf of the EUROASPIRE Investigators
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.

20 August 2016 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
KKKornelia P. Kotseva
Kornelia P. Kotseva
DBDirk De Bacquer
Dirk De Bacquer
GBGuy De Backer
Guy De Backer
LRLars Rydén
Lars Rydén
CJCatriona Jennings
Catriona Jennings
OIOn Behalf Of The Euroaspire Investi
On Behalf Of The Euroaspire Investi
European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV in primary care was a cross-sectional survey carried out by the European Society of Cardiology, EURObservational Research Programme in 2014–2015 in 71 centres from 14 European countries. The main objective was to determine whether the 2012 Joint European Societies’ guidelines on cardiovascular disease (CVD) prevention in people at high CVD risk have been followed in clinical practice. Patients without a history of atherosclerotic disease started on either blood pressure and/or lipid and/or glucose-lowering treatments were identified and interviewed at least six months after the start of medication. Medical notes of 6700 patients were reviewed, and 4579 patients (58.7% women; mean age 58.8 (standard deviation (SD) 11.3) years) interviewed (interview rate 68.3%). Overall, 16.6% were smokers, 39.9% were overweight (body mass index (BMI)≥25 and <30 kg/m2), 43.5% obese (BMI ≥30 kg/m2) and 63.9% centrally obese (waist circumference of ≥88 cm for women, ≥102 cm for men). The medical risk factor control was very poor, with less than half (42.8%) of the patients on blood pressure lowering medication reaching the target of <140/90 mm Hg (<140/80 mm Hg in people with self-reported diabetes). Among treated dyslipidaemic patients only 32.7% attained the low-density lipoprotein (LDL)-cholesterol target of <2.5 mmol/l. Among people treated for type 2 diabetes mellitus, 58.5% achieved the glycated haemoglobin (HbA1c) target of <7.0%. The EUROASPIRE IV survey shows that large proportions of patients at high CVD risk have unhealthy lifestyle habits and uncontrolled blood pressure, lipids and diabetes. The present data make it clear that more efforts must be taken to improve cardiovascular prevention in people at high CVD risk.

1 October 2015 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
OIOn behalf of the EUROASPIRE Investigators
On behalf of the EUROASPIRE Investigators
VGViveca Gyberg
Viveca Gyberg
DBDirk De Bacquer
Dirk De Bacquer
GBGuy De Backer
Guy De Backer
CJCatriona Jennings
Catriona Jennings
DVDusko Vulic
Dusko Vulic
In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. A total of 6187 patients (18–80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012–2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys. A total of 2846 (46 %) patients had no diabetes, 1158 (19 %) newly diagnosed diabetes and 2183 (35 %) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60 %, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54 % and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28 %. Patients with newly diagnosed and previously known diabetes reached an HbA1c 9.0 % (>75 mmol/mol). Of the patients with diabetes 69 % reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40 %) and only 27 % of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets. Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease.

24 February 2016 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
SIS. V. Ivanova
S. V. Ivanova
ESE. L. Shkolnik
E. L. Shkolnik
YKYu. V. Kotovskaya
Yu. V. Kotovskaya
VMV. A. Milyagin
V. A. Milyagin
AМArray Ю. Мареев
Array Ю. Мареев
Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике

1 October 2009 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
MCMarie-Therese Cooney
Marie-Therese Cooney
ADAlexandra Dudina
Alexandra Dudina
PWPeter Whincup
Peter Whincup
SCSimon Capewell
Simon Capewell
AMAlessandro Menotti
Alessandro Menotti
SISCORE Investigators
SCORE Investigators
Background Options for the prevention of cardiovascular disease, the greatest global cause of death, include population preventive measures (the Rose approach),...

1 January 2017 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ROR. G. Oganov
R. G. Oganov
IDI. N. Denisov
I. N. Denisov
VSV. I. Simanenkov
V. I. Simanenkov
IBI. G. Bakulin
I. G. Bakulin
NBN. V. Bakulina
N. V. Bakulina
ЮКЮ. В. Котовская
Ю. В. Котовская
КОМОРБИДНАЯ ПАТОЛОГИЯ В КЛИНИЧЕСКОЙ ПРАКТИКЕ. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ